Eléments de l'association

	Olivier Rascol	56
	neuroprotection	39
	Olivier Rascol *Sauf* neuroprotection"	53
	neuroprotection *Sauf* Olivier Rascol"	36
	Olivier Rascol Et neuroprotection	3
	Olivier Rascol Ou neuroprotection	92
	*Corpus*	4598

List of bibliographic references

Number of relevant bibliographic references: 3.

Ident.	Authors (with country if any)	Title
000567	Anthony H. V. Schapira [Royaume-Uni] ; Stefan Albrecht [Allemagne] ; Paolo Barone [Italie] ; Cynthia L. Comella [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Kenneth Marek [États-Unis]	Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study
000994	A. H. Schapira [Royaume-Uni] ; Yves Agid [France] ; P. Barone [Italie] ; P. Jenner [Royaume-Uni] ; M. R. Lemke [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; H. Reichmann [Allemagne] ; E. Tolosa [Espagne]	Perspectives on recent advances in the understanding and treatment of Parkinson’s disease
000E78	C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France]	A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024